Open AccessVision Loss after Intravitreal Injection of Autologous “Stem Cells” for AMD
Author(s) -
Ajay E. Kuriyan,
Thomas A. Albini,
Justin H. Townsend,
Marianeli Rodriguez,
Hemang K. Pandya,
Robert E. Leonard,
M. Brandon Parrott,
Philip J. Rosenfeld,
Harry W. Flynn,
Jeffrey L. Goldberg
Publication year - 2017
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1609583
Subject(s) - medicine , visual acuity , retinal detachment , stem cell , ophthalmology , vitreous hemorrhage , adipose tissue , diabetic retinopathy , surgery , retinal , diabetes mellitus , genetics , biology , endocrinology
Adipose tissue-derived "stem cells" have been increasingly used by "stem-cell clinics" in the United States and elsewhere to treat a variety of disorders. We evaluated three patients in whom severe bilateral visual loss developed after they received intravitreal injections of autologous adipose tissue-derived "stem cells" at one such clinic in the United States. In these three patients, the last documented visual acuity on the Snellen eye chart before the injection ranged from 20/30 to 20/200. The patients' severe visual loss after the injection was associated with ocular hypertension, hemorrhagic retinopathy, vitreous hemorrhage, combined traction and rhegmatogenous retinal detachment, or lens dislocation. After 1 year, the patients' visual acuity ranged from 20/200 to no light perception.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom